How has been the historical performance of Nath Bio-Genes?

Answer:The historical performance of Nath Bio-Genes shows a consistent growth trend in net sales and profitability over the past four years, culminating in the fiscal year ending March 2025.

Breakdown:
Nath Bio-Genes reported net sales of 364.91 Cr in March 2025, an increase from 332.62 Cr in March 2024, 301.36 Cr in March 2023, and 278.36 Cr in March 2022. The total operating income mirrored this growth, reaching 364.91 Cr in March 2025. Total expenditure, excluding depreciation, also rose to 315.11 Cr in March 2025 from 282.76 Cr in March 2024, reflecting increased manufacturing and distribution expenses. Operating profit (PBDIT) was 54.35 Cr in March 2025, slightly up from 50.49 Cr in March 2024, while profit before tax improved to 40.04 Cr from 38.12 Cr. Profit after tax reached 38.06 Cr in March 2025, compared to 36.17 Cr in March 2024, indicating a positive trend in profitability. The earnings per share (EPS) were 20.32 in March 2025, down from 20.85 in March 2024, yet significantly improved from a loss of -35.46 in March 2022. The company also demonstrated a positive cash flow, with a net cash inflow of 11.00 Cr in March 2025, up from 39.00 Cr in March 2024, and closing cash and cash equivalents increased to 88.00 Cr from 77.00 Cr in the previous year. Overall, Nath Bio-Genes has shown a recovery and growth trajectory in its financial performance over the last four years.